Panelists discuss how overcoming resistance to EGFR TKIs requires next-generation inhibitors and more individualized treatment strategies.
Jorge Garcia, PharmD, MS, MHA, MBA, FACHE
Advertisement
Articles by Jorge Garcia, PharmD, MS, MHA, MBA, FACHE
Panelists discuss how EGFR mutation profiling guides targeted first-line NSCLC therapy and shifts care toward precision medicine.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Guidelines for Bronchiectasis Highlight Multiple Treatment Methods
2
FDA Approves Belantamab Mafodotin Combo for Relapsed or Refractory Multiple Myeloma
3
Many US Health Care Workers Face Poverty, Food Insecurity, and Housing Instability
4
Combination Therapy Proves More Effective in NSCLC Compared With Chemotherapy
5
